Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.40
(
3.58%
)
Bitcoin
70,053.72
(
-1.67%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

turtlepower

Send PM Follow Ignore
Followers 1
Posts 1114
Boards Moderated 0
Alias Born 04/07/2009

turtlepower

Re: mcbio post# 130400

Monday, 11/07/2011 11:25:52 AM

Monday, November 07, 2011 11:25:52 AM

Post# of 257257
EXEL - IMO the article is incomplete since it does not include the impact of competition to 184. Given the success of MDV3100 (albeit at a different stage of the disease) the CRPC market is now getting crowded. 184 will have to differentiate itself and prove to be better than drugs like 3100 that will already be in the market by the time the 307 trial concludes.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now